News & Videos - SOSEI CO LTD. SOLTF - English - Page 2

New name expresses the Company’s vision to lead the next era of medicine - from Japan, for Japan, and by extension, to the world – and its mission to accelerate the development of life-changing medicines, by investing in science and technology Sosei Group and its subsidiaries, Heptares Therapeutics and Idorsia Pharmaceuticals Japan and Korea, have all been renamed under the Nxera Pharma brand Tokyo, Japan and Cambridge, UK, 1 April 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the...

Tokyo, Japan and Cambridge, UK, 27 March 2024 – Sosei Group Corporation (“the Company”; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the Company’s 34th Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held today in Tokyo. In addition, the “Partial Amendment to the Articles of Incorporation (Change of Corporate Name)” was approved at the Annual Shareholder’s Meeting. With this approval, the...

HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces it has dosed the first subject in a Phase 1 trial evaluating its novel EP4 receptor agonist, HTL0033744 (HTL’744) for the treatment of Inflammatory Bowel Disease (IBD), a therapeutic area where there remains significant unmet need for...

GPR35 is a novel target with an established genetic association to IBD UK regulatory approval received to commence first-in-human studies Return of rights follows change in immunology research strategy by GSK Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces it has regained full ownership from GSK of HTL0027477 (formerly GSK4381406), a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in...

Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophrenia Sosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK,...

Tokyo, Japan and Cambridge, UK, 6 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces that Formosa Pharmaceuticals, Inc. (“Formosa”) has received approval from the US Food & Drug Administration (“FDA”) for clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-operative inflammation and pain following ocular surgery. The milestone has triggered a US$2.5 million payment to Sosei Heptares from Formosa....

Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of Directors resolved to change the corporate names of the Company and its subsidiaries and the location of the head office of the Company. At the same meeting, the Board resolved to merge Idorsia Pharmaceuticals Japan Ltd ("IPJ") and Sosei Co. Ltd., both of which are wholly owned consolidated...

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023. The full report can be found by clicking here . Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been...

Tokyo, Japan and Cambridge, UK, 22 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 12 months ended 31 December 2023 on Tuesday, 13 February 2024. The Company will host a live webinar presentation with Chris Cargill, President and CEO, Hironoshin Nomura, CFO, Matt Barnes, Head of UK R&D and Satoshi Tanaka, Executive Officer and Executive Vice President of Sosei Heptares...

Tokyo, Japan and Cambridge, UK, 5 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces the appointment of Mr. Toshihiro Maeda as Chief Operating Officer (“COO”). Mr. Maeda joins from Bristol Myers Squibb (“BMS”), where he led a Business Unit and was instrumental in the post-merger integration of Celgene’s businesses and commercial strategies for the combined group in Japan. Mr. Maeda brings with him a breadth of global...

Tokyo, Japan and Cambridge, UK, 21 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), announces its President & CEO, Chris Cargill, will present at the 42 nd Annual J.P. Morgan Healthcare Conference. The presentation will take place in-person at the JW Marriott Hotel, San Francisco Union Square, and via webcast at 1:30pm Pacific Standard Time on Wednesday, 10 January 2024. An audio link to the Company’s webcast presentation can be accessed here ....

PIVLAZ™, a new drug for prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH), approved in South Korea PIVLAZ will become commercially available in South Korea in early 2025 Tokyo, Japan, Seoul, South Korea, and Cambridge, UK, 7 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces that PIVLAZ™ (clazosentan sodium) 150 mg has received marketing approval from the Ministry of Food and Drug Safety...

Both NBI-1117569 (an M4-preferring agonist) and NBI-1117567 (an M1-preferring agonist) are investigational, oral, muscarinic agonists discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditions Neurocrine Biosciences confirmed a Phase 1 clinical study of NBI-1117569 has started and a Phase 1 study of NBI-1117567 will be initiated in 2024 Tokyo, Japan and Cambridge, UK, 6 December 2023 – Sosei Group Corporation (“the Company”; TSE: 4565),...

GPR35 is a novel target with an established genetic association to IBD UK regulatory approval received to commence first-in-human studies Independent commercial analysis supports a worldwide peak sales opportunity of more than US$3 billion for GSK4381406 with its unique target product profile Tokyo, Japan and Cambridge, UK, 24 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces it has initiated discussions with GSK to regain full ownership...

Tokyo, Japan, Cambridge, UK and New York, USA – 10 November 2023 – Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and Kallyope, a clinical stage biotechnology company discovering and developing novel, oral small-molecule therapeutics for diseases with high unmet need, today announced the successful identification, validation and nomination of a first G protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for...

Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2023. The full report can be found by clicking here . Chris Cargill, President & CEO of Sosei Heptares, commented: “The third quarter has been an exciting and transformational period for the Group following the acquisition of...

Tokyo, Japan and Cambridge, UK, 7 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces its President & CEO, Chris Cargill, and Matt Barnes, Head of UK R&D, will participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference on Tuesday, 14 November at 10:30 a.m. GMT / 5:30 a.m. ET / 7:30 p.m. JST. During the event, Mr. Cargill and Dr. Barnes will present the Company’s strategy, recent progress and expected upcoming...

PF-06954522 was introduced into Pfizer’s Internal Medicine focused clinical pipeline as part of its Q3 2023 results presentation Tokyo, Japan and Cambridge, UK, 06 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) has been notified by Pfizer that it has entered a new oral small molecule GLP-1 receptor agonist into a Phase 1 clinical trial. PF-06954522 was discovered by Pfizer scientists during a multi-target research collaboration in which Pfizer...

Tokyo, Japan and Cambridge, UK, 31 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will receive a US$3.75 million milestone payment under the 2019 multi-target Research Collaboration and License Agreement with Genentech, a member of the Roche Group. The discovery-based payment is related to progression of a potential first-in-class project targeting an undisclosed G protein-coupled receptor (“GPCR”). Genentech will now be responsible for...

NDA includes robust data from a Phase 3 trial that demonstrated efficacy of daridorexant on improving Total Sleep Time and Latency for Sleep Onset, while maintaining a favorable safety profile Sosei Heptares to receive JPY 1.5 billion milestone revenue in relation to the submission Tokyo, Japan and Cambridge, UK, 31 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces that Idorsia Pharmaceuticals Japan Ltd. (“Idorsia Japan”), a Sosei Group...